Navigation Links
Halozyme Therapeutics Realigns Management
Date:12/3/2010

resident and CEO. "With the promotion of Mike Shepard to chief scientific officer, our scientific leadership has been placed in the capable hands of a proven biotechnology product innovator."

About Halozyme Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, and with Baxter BioScience to apply Enhanze technology to immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning our potential opportunities and implementation of our strategy) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identifi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- Gateway Analytical announced today that ... Annual Global Pharma Manufacturing Summit in ... . The Global Pharma Manufacturing Summit offers a ... and biologic pharmaceutical manufacturing. The conference is focused ... face, such as the increasing pressure to grow ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... , Aug. 28, 2014  Robotic surgery ... and media, both for the promise of improved ... The quick deployment of surgical robots and market ... prompting facilities to evaluate their robotic surgery training ... surgical team.    ECRI Institute ( ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... 8, 2012 /PRNewswire-iReach/ -- Reimbursement strategy has ... and commercialization plan. For new product launches it is ... of life benefits versus comparators to payers, providers and ... highlight these trends:  IMPACT OF 2009-2011 GLOBAL ...
... MINNEAPOLIS, May 8, 2012  Coloplast North America today announced ... that Generic Medical Devices, Inc. (GMD) was infringing on ... method for treating stress urinary incontinence in women. Using ... to help women regain control of their bladder. ...
Cached Medicine Technology:Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies 2Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc. 2
(Date:8/29/2014)... (PRWEB) August 29, 2014 VHA Central ... for excellence in clinical care, honoring nine facilities for ... patient experience. , “At Novant Health, providing quality, affordable ... priority” said Tom Zweng, MD, executive vice president and ... to provide a remarkable experience for each and every ...
(Date:8/29/2014)... For the fifth year in a ... be observing September 26th as Mesothelioma Awareness Day, by ... York. , Members of the community who wish ... Foundation will be providing t-shirts and signs to participating ... members have received attention from Al Roker ...
(Date:8/29/2014)... 2014 Parker Waichman LLP, a national ... the rights of victims who have been injured by ... announced new regulations for all hydrocodone combination products. According ... report dated August 21, 2014, the DEA will be ... federal law. , The long-awaited announcement comes after ...
(Date:8/29/2014)... Empty Nest Syndrome on Dr. Carol ... , Mothers and fathers, who dedicated the last ... laughing and sweating through parenting, launch their college ... Relief and parenting pride intermix with loss, depression ... Carol Francis as a Clinical Psychologist has helped ...
(Date:8/29/2014)... 2014 Bedros Keuilian recently stepped outside his ... expert on the new Spike TV reality show, Gym ... searched Google for an expert in boot camp marketing and ... Now Keuilian has just released a webinar explaining how fitness ... status as experts and increase their client base. , In ...
Breaking Medicine News(10 mins):Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 3Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 2Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 3
... 1 Arete Therapeutics Inc. today,announced the initiation ... lead compound,AR9281, for the treatment of hypertension. AR9281 ... (s-EH), a novel target,for the treatment of hypertension. ... volunteers and will evaluate the safety, tolerability,pharmacokinetics and ...
... 1 Amira Pharmaceuticals, Inc. announced,completion of the ... discovered oral drug candidate for the treatment of ... announced the start,of a Phase 1 trial for ... the,same inflammatory response. AM103 and AM803 are ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... BASINGSTOKE, England and PHILADELPHIA, November 1, Shire plc (LSE: SHP, ... for the third,quarter 2007. Q3 2007 Financial Highlights ... Total revenues up 35% to $608.7 million; - Net ... and - 2007 revenue growth now expected to be ...
... Innovative Approach to Preventing Kidney Damage during ... ... (Amex: PLC ), a,company focused on innovative cardiac and vascular ... Renal Week, the American Society of Nephrology,s 40th,Annual Meeting and Scientific ...
... of the cells might lead to treatments, researchers say , THURSDAY, ... found stem cells within the intervertebral discs of the human spine. ... stem cells to help repair degenerating discs in order to treat ... the Nov. 1 issue of the journal Spine . , ...
Cached Medicine News:Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 31
... speed and accuracy allow clinical staff ... timely manner - something everyone in ... In fact, the Rapidlab 1200 delivers ... one minute. Its maintenance-free, cartridge-based system ...
... Fibertom is a 60 watt diode continuous wave ... of Diode Power Bar technology and 940 nm ... laser treatment for varicose veins and a variety ... includes unique safety features including the LPS, Light ...
... 28 Hue test studies the characteristic ... Farnsworth D15, however this 28 hue ... of sensitivity. Case comes with a ... readable. Kit includes laminated scoring template ...
... disc test for detecting and grading ... minutes for quantitative estimation of saturation ... sensitive to and specific for differences ... Combined with Ishiharas pseudo-isochromatic plates, discriminates ...
Medicine Products: